Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Reexamination Certificate
2007-11-27
2007-11-27
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
C424S001110, C424S009100, C424S001650
Reexamination Certificate
active
10361026
ABSTRACT:
The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.
REFERENCES:
patent: 3927193 (1975-12-01), Hansen et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4474893 (1984-10-01), Reading
patent: 4479895 (1984-10-01), Auditore-Hargreaves
patent: 4624846 (1986-11-01), Goldenberg
patent: 4818709 (1989-04-01), Primus et al.
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5283342 (1994-02-01), Gustavson et al.
patent: 5420105 (1995-05-01), Gustavson
patent: 5474772 (1995-12-01), Maddock
patent: 5482698 (1996-01-01), Griffiths
patent: 5525338 (1996-06-01), Goldenberg
patent: 5736119 (1998-04-01), Goldenberg et al.
patent: 5846741 (1998-12-01), Griffiths et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 7011812 (2006-03-01), Griffiths et al.
patent: 2003/0198595 (2003-10-01), Goldenberg et al.
patent: 0 496 074 (1992-07-01), None
patent: 3-503898 (1991-08-01), None
patent: 5501543 (1993-03-01), None
patent: WO 94/23759 (1994-10-01), None
patent: WO 97/41898 (1997-11-01), None
Golub et al, Science, Oct. 15, 1999, vol. 286, pp. 531-537.
Barbet, J., et al., “Radioimmunodetection of Medullary thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium Bispecific Antibody,” The Journal of Nuclear Medicine, vol. 39, No. 7, Jul. 1998, pp. 1172-1178.
Janevik-Ivanovska, E., et al., “Bivalent Hapten-Bearing Peptides Designed for Iodine-131 Pretargeted Radioimmunotherapy” Bioconjugate Chem. 1997, 8, 526-533.
Schuhmacher, Jochen, et al., “Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/ anti-Ga chelate antibodies and immunoscintigraphy with PET” Nuclear Medicine and Biology 28 (2001) 821-828.
Gautherot, Emmunuel, et al., “Immunohistology of Carcinoembryonic Antigen (CEA)-expressing Tumors Grafted in Nude Mice after Radioimmunotherapy with 131l-labeled Bivalent Hapten and Anti-CEZ x Antihapten Bispecific Antibody,” Clinical Cancer Research vol. 5, 3177s-3182s, Oct. 1999 (Suppl.).
Karacay, H., “Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti-[In-DTPA] Bispecific Antibody Construct and a 99mTc-/188Re-Labeled Peptide” Bioconjugate Chem. 2000, 11, 842-854.
Goldenberg David M.
Griffiths Gary L.
Hansen Hans J.
Faegre & Benson LLP
Immunomedics Inc.
Jones Dameron L.
Nakashima Richard A.
LandOfFree
Targeted combination immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted combination immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted combination immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3813274